Identification of six new susceptibility loci for invasive epithelial ovarian cancer

[1]  B. Stranger,et al.  Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. , 2014, Human molecular genetics.

[2]  D. Easton,et al.  Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants , 2013, Journal of Medical Genetics.

[3]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[4]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[5]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[6]  Brooke L. Fridley,et al.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.

[7]  A. Whittemore,et al.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 , 2013, Nature Communications.

[8]  W. Chung,et al.  Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk , 2013, PLoS genetics.

[9]  D. Altshuler,et al.  Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk , 2013, PLoS genetics.

[10]  P. Viganò,et al.  An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis , 2012, Journal of Medical Genetics.

[11]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[12]  R. Vierkant,et al.  ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium , 2012, Cancer Causes & Control.

[13]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[14]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[15]  C. Chakraborty,et al.  Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells , 2012, Journal of cellular physiology.

[16]  D. Easton,et al.  Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of High‐Risk Mutations , 2012, Genetic epidemiology.

[17]  A. Berchuck,et al.  Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC) , 2012, Journal of internal medicine.

[18]  J. S. Hoffman,et al.  Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers , 2012, Human mutation.

[19]  W. Chung,et al.  Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[20]  O. Delaneau,et al.  A linear complexity phasing method for thousands of genomes , 2011, Nature Methods.

[21]  C. Shriver,et al.  Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study , 2012, BMC Medical Genetics.

[22]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[23]  Nancy F. Hansen,et al.  Predisposition to Cancer Caused by Genetic and Functional Defects of Mammalian Atad5 , 2011, PLoS genetics.

[24]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[25]  R. Drapkin,et al.  Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells , 2011, Journal of visualized experiments : JoVE.

[26]  R. Vierkant,et al.  LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. , 2011, Cancer research.

[27]  D. Gerrelli,et al.  Human RSPO1/R-spondin1 Is Expressed during Early Ovary Development and Augments β-Catenin Signaling , 2011, PloS one.

[28]  Summer S. Han,et al.  Inference from a multiplicative model of joint genetic effects for [corrected] ovarian cancer risk. , 2011, Journal of the National Cancer Institute.

[29]  F. Couch,et al.  Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. , 2011, Journal of the National Cancer Institute.

[30]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[31]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[32]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[33]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[34]  D. Easton,et al.  Evaluating the power to discriminate between highly correlated SNPs in genetic association studies , 2010, Genetic epidemiology.

[35]  I. Jacobs,et al.  Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. , 2010, Neoplasia.

[36]  A. D’Andrea,et al.  Human ELG1 Regulates the Level of Ubiquitinated Proliferating Cell Nuclear Antigen (PCNA) through Its Interactions with PCNA and USP1* , 2010, The Journal of Biological Chemistry.

[37]  A. Dutra,et al.  DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity , 2009, Cell cycle.

[38]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[39]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[40]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[41]  P. Møller,et al.  High Risk for Ovarian Cancer in a Prospective Series Is Restricted to BRCA1/2 Mutation Carriers , 2008, Clinical Cancer Research.

[42]  J. Vandekerckhove,et al.  Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. , 2008, Biochemical and biophysical research communications.

[43]  K. Tomizuka,et al.  R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. , 2008, Human molecular genetics.

[44]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[45]  Joaquín Dopazo,et al.  Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeffect and PupaSuite databases , 2007, Nucleic Acids Res..

[46]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[47]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[48]  E. Dellambra,et al.  R-spondin1 is essential in sex determination, skin differentiation and malignancy , 2006, Nature Genetics.

[49]  Yan Ping Yu,et al.  Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. , 2006, Cancer research.

[50]  Joaquín Dopazo,et al.  PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes , 2006, Nucleic Acids Res..

[51]  L. Bourguignon,et al.  Hyaluronan-CD44 Interaction with IQGAP1 Promotes Cdc42 and ERK Signaling, Leading to Actin Binding, Elk-1/Estrogen Receptor Transcriptional Activation, and Ovarian Cancer Progression* , 2005, Journal of Biological Chemistry.

[52]  I. Jacobs,et al.  A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro , 2004, Laboratory Investigation.

[53]  D. Landsittel,et al.  Expression of Myopodin Induces Suppression of Tumor Growth and Metastasis , 2004 .

[54]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[55]  C. Cordon-Cardo,et al.  Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome , 2003, Oncogene.

[56]  I. Jacobs,et al.  Histopathologic Features of Genetically Determined Ovarian Cancer , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[57]  M. Becich,et al.  Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. , 2001, The American journal of pathology.

[58]  D. Easton,et al.  A systematic review and meta‐analysis of family history and risk of ovarian cancer , 1998, British journal of obstetrics and gynaecology.

[59]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[60]  R. Sankila,et al.  Cancer incidence in the first-degree relatives of ovarian cancer patients. , 1996, British Journal of Cancer.